#Blood Screening Market Research | Explore Tumblr posts and blogs

latestmarketresearchnews · 2 days ago

Text

Blood Screening Market 2030 Share, Revenue, Drivers, Trends and Influence Factors

The global blood screening market, valued at USD 3.40 billion in 2024, is projected to expand at a compound annual growth rate (CAGR) of 11.9% from 2025 to 2030. This anticipated growth is largely due to a global increase in blood donations, which heightens the need for rigorous screening processes to detect transfusion-transmissible infections and ensure patient safety. Advances in technology, especially in automation and molecular platforms, are making blood screening faster, more accurate, and more efficient. Additionally, the growing prevalence of infectious diseases, coupled with government initiatives to promote safe blood practices, has driven public awareness of the importance of blood screening. These factors collectively contribute to the market’s expansion.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Regional Insights:

North America Blood Screening Market Trends

In 2024, North America dominated the global blood screening market, accounting for the largest revenue share at 38.4%. The region’s healthcare infrastructure is highly advanced, with a strong focus on patient safety, supported by cutting-edge blood screening technology. Growing awareness around the importance of early disease detection has prompted healthcare providers in North America to prioritize routine blood screening. The collaboration between public health organizations and private sectors in the U.S. and Canada further enhances access to quality blood screening services, sustaining growth in this region.

U.S.

The U.S. market led the North American blood screening sector in 2024, driven by a high volume of blood donations and stringent regulations for blood safety. The country’s focus on secure blood transfusions creates demand for comprehensive blood screening methods. Innovations in testing technology contribute to higher accuracy and faster processing times, while favorable reimbursement policies encourage healthcare providers to adopt the latest screening technologies, ultimately improving public health outcomes.

Asia Pacific Blood Screening Market Trends

The Asia Pacific blood screening market is expected to experience the fastest growth, with a projected CAGR of 13.7% over the forecast period. Factors such as increasing healthcare awareness, economic growth, and significant investments in healthcare infrastructure are enhancing access to blood screening services in the region. The rising rates of infectious diseases have intensified the need for effective blood screening methods, and government initiatives promoting preventive healthcare are further driving demand. This makes Asia Pacific a key market for potential innovation and expansion in blood screening technology.

Japan

Japan’s blood screening market is set to grow substantially, supported by the country’s advanced technology sector and focus on preventive healthcare. Increased public awareness about the importance of health check-ups and blood safety, combined with a growing aging population, has driven demand for diagnostic services to manage chronic conditions. Government support for blood donation and improved screening technologies upholds Japan’s high standards in blood safety and contributes to market growth.

Europe Blood Screening Market Trends

Europe’s blood screening market is projected to expand significantly, largely due to stringent regulatory standards and a strong focus on patient safety. Many countries in Europe have established robust blood testing frameworks that emphasize quality control and risk management. The rise in infectious diseases has heightened the demand for advanced screening technologies, and public-private partnerships have enhanced access to these innovations across the continent, promoting overall public health.

Germany

In Germany, the blood screening market benefits from a strong emphasis on innovation and quality assurance within its healthcare system. Rigorous testing protocols ensure accurate and reliable results, while increased awareness of blood-borne diseases drives demand for effective screening methods. The German government’s initiatives to promote routine health check-ups, coupled with the country’s active research environment, support advancements in diagnostic technology and improve the effectiveness of blood screening practices.

Browse through Grand View Research's Category Clinical Diagnostics Industry Research Reports.

The global saliva collection and diagnostics market size was estimated at USD 818.9 million in 2024 and is projected to grow at a CAGR of 4.7% from 2025 to 2030.

The global cholesterol testing products and services market size was estimated at USD 19.85 billion in 2024 and is projected to grow at a CAGR of 8.4% from 2025 to 2030.

Key Companies & Market Share Insights:

Leading players in the blood screening market, including Bio-Rad Laboratories, Inc., Hoffmann-La Roche Ltd., Grifols, S.A., and Abbott Laboratories, employ various strategies to maintain competitiveness and expand their market reach. These companies pursue strategic collaborations to drive innovation, engage in mergers and acquisitions to enhance capabilities, and frequently launch new products to address evolving healthcare needs.

Abbott Laboratories

Abbott Laboratories is a global leader in medical technology, offering specialized equipment that leverages advanced blood screening components to ensure high durability and lightweight properties. Beyond blood screening, Abbott operates in other medical sectors, such as laboratory diagnostics, cardiovascular devices, diabetes care, and nutrition. This diverse portfolio positions Abbott as a prominent player in healthcare, addressing a broad spectrum of medical needs.

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is a key player in diagnostics, developing instruments that integrate blood screening materials for enhanced performance and reliability. Apart from blood screening, Bio-Rad is also involved in areas like quality control, gene expression analysis, and protein purification. This wide range of expertise strengthens Bio-Rad’s position as a leading company in both research and clinical diagnostics, allowing it to serve a variety of healthcare needs across global markets.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Research #Blood Screening Market Forecast #Blood Screening Market Overview

0 notes

researchreportinsight · 2 days ago

Text

Blood Screening Industry 2030 Size, Share, Business Growth, Demand and Applications

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

Regional Insights:

North America Blood Screening Market Trends

U.S.

Asia Pacific Blood Screening Market Trends

Japan

Europe Blood Screening Market Trends

Germany

Browse through Grand View Research's Category Clinical Diagnostics Industry Research Reports.

The global saliva collection and diagnostics market size was estimated at USD 818.9 million in 2024 and is projected to grow at a CAGR of 4.7% from 2025 to 2030.

The global cholesterol testing products and services market size was estimated at USD 19.85 billion in 2024 and is projected to grow at a CAGR of 8.4% from 2025 to 2030.

Key Companies & Market Share Insights:

Abbott Laboratories

Bio-Rad Laboratories, Inc.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research.

#Blood Screening Market Research #Blood Screening Market Forecast #Blood Screening Market Overview

0 notes

marketresearchreportinsight · 2 days ago

Text

Blood Screening Industry 2030 Size Outlook, Growth Insight, Share, Trends

#Blood Screening Market Forecast #Blood Screening Market Overview #Blood Screening Market Research

0 notes

snehahealthcareblogs · 2 years ago

Link

#allied market research #blood #blood collection #plasma collection #blood screening

0 notes

mostlysignssomeportents · 10 months ago

Text

Brinklump Linkdump

Catch me in Miami! I'll be at Books and Books in Coral Gables on Jan 22 at 8PM.

Life comes at you fast, links come at you faster. Once again, I've arrived at Saturday with a giant backlog of links I didn't fit in this week, so it's time for a linkdump, the 14th in the series:

https://pluralistic.net/tag/linkdump/

It's the Year of Our Gourd twenty and twenty-four and holy shit, is rampant corporate power rampant. On January 1, the inbred droolers of Big Pharma shat out their annual price increases, as cataloged in 46Brooklyn's latest Brand Drug List Price Change Box Score:

https://www.46brooklyn.com/branddrug-boxscore

Here's the deal: drugs that have already been developed, brought to market, and paid off are now getting more expensive. Why? Because the pharma companies have "pricing power," the most reliable indicator of monopoly. Ed Cara rounds up the highlights for Gizmodo:

https://gizmodo.com/ozempic-wegovy-wellbutrin-oxycontin-drug-price-increase-1851179427

What's going up? Well, Ozempic and other GLP-1 agonists. These drugs have made untold billions for their manufacturers, so naturally, they're raising the price. That's how markets work, right? When firms increase the volume of a product, the price goes up? Right? Other drugs that are going up include Wellbutrin (an antidepressant that's also widely used in smoking cessation) and the blood thinner Plavix. I mean, why the hell not? These companies get billions in research subsidies, invaluable government patent privileges, and near-total freedom to abuse the patent system with evergreening:

https://pluralistic.net/2023/11/23/everorangeing/#taste-the-rainbow

The most amazing things about monopolies is how the contempt just oozes out of them. It's like these guys can't even pretend to give a shit. You want guillotines? Because that's how you get guillotines.

Take Apple. They just got their asses handed to them in court by Epic, who successfully argued that Apple's rule requiring everyone who sells through the App Store to use Apple's payment processor and pay Apple 30% out of every dollar they bring in was an antitrust violation. Epic won, then won the appeal, then SCOTUS told Apple they wouldn't hear the case, so that's that.

Right? Wrong. Apple's pulled a malicious compliance stunt that could shame the surly drunks my great-aunt Lisa used to boss in the Soviet electrical engineering firm she ran. Apple has announced that app companies that process transactions using their own payment processors on the web must still pay Apple a 27% fee for every dollar their process:

https://finance.yahoo.com/news/apples-app-store-rule-changes-draw-sharp-rebuke-from-critics-150047160.html

In addition, Apple will throw a terrifying FUD-screen up every time a user clicks a payment link that goes to the web:

https://www.jwz.org/blog/2024/01/second-verse-same-as-the-first/

This is obviously not what the court had in mind, and there's no way this will survive the next court challenge. It's just Apple making sure that everyone knows it hates us all and wants us to die. Thanks, Tim Apple, and right back atcha.

Not to be outdone in the monopolistic mustache-twirling department, Ubisoft just announced that it is going to shut down its driving simulator game The Crew, which it sold to users with a "perpetual license":

https://www.youtube.com/watch?v=VIqyvquTEVU

This is some real Darth Vader MBA shit. "Yeah, we sold you a 'perpetual license' to this game, but we're terminating it. I have altered the deal. Pray I don't alter it further":

https://pluralistic.net/2023/10/26/hit-with-a-brick/#graceful-failure

Ubisoft sure are innovators. They've managed the seemingly impossible feat of hybridizing Darth Vader and Immortan Joe. Ubisoft's head of subscriptions, the guillotine-ready Philippe Tremblay, told GamesIndustry.biz that gamers need to get "comfortable" with "not owning their games":

https://www.gamesindustry.biz/the-new-ubisoft-and-getting-gamers-comfortable-with-not-owning-their-games

Or, as Immortan Joe put it: "Do not, my friends, become addicted to water. It will take hold of you, and you will resent its absence!"

Capitalism without constraint is enshittification's handmaiden, and the latest victim is Ello, the "indie" social media startup that literally promised – on the sacred honor of its founders – that it would never sell out its users. When Ello took VC and Andy Baio questioned how this could be squared with this promise, the founders mocked him and others for raising the question. Their response boiled down to "we are super-chill dudes and you can totally trust us."

They raised more capital, and used that to create a nice place for independent artists, who piled into the platform and provided millions of unpaid hours of creative labor to help the founders increase its value. The founders and their investors turned the company into a Public Benefit Corporation, which meant they had an obligation to serve the public benefit.

But then they took more investment money and simply (and silently) sold their assets to a for-profit. Struggling to raise capital, the founders opted to secretly sell the business to a sleazy branding company called Talenthouse. Its users didn't know about the change, though the site sure had a lot of Talenthouse design competitions all of a sudden.

Finally, the company announced the change as the last founders left. Rather than announcing that the new owners were untrustworthy scum, warning their users to get their data and get out, the founders posted oblique, ominous statements to Instagram. The company started stiffing the winners of those design competitions. Then, one day, poof, Ello disappeared, taking all its users' data with it. Poof:

https://waxy.org/2024/01/the-quiet-death-of-ellos-big-dreams/

I'm sure the founders' decisions each seemed reasonable at the moment. That's every terrible situation arises: you rationalize that a single compromise isn't that big of a deal, and then you do the same for the next compromise, and the next, and the next. Pretty soon, you're betraying everyone who believed in you.

One answer to this is "Ulysses pacts": making binding commitments to do right before you are tempted. Throw away all your Oreos when you go on a diet and you can't be tempted to eat a whole sleeve of them at 2AM. License your software under the GPL and your investors can't force you to make it proprietary. Set up a warrant canary and the feds can't force you to keep their spying secret:

https://locusmag.com/2021/01/cory-doctorow-neofeudalism-and-the-digital-manor/

If the founders were determined to build a trustworthy, open, independent company, they could have published their quarterly books, livestreamed their staff meetings, built data-export tools that emailed users every week with a link to download everything they'd posted since the last week. Merely halting any of these practices would have been a signal that things were wrong. Anyone who says they won't be tempted in the moment to make a "reasonable" compromise in the hopes of recovering whatever they're trading away by living to fight another day is bullshitting you, and possibly themself.

The inability to project the consequences of your bad decisions in the future is the source of endless mischief and heartbreak. Take movie projectors. A couple decades ago, the studio cartel established a standard for digital movie distribution to cinematic exhibitors called the Digital Cinema Initiative. Because studio executives are more worried about stopping piracy than they are about making sure that people who pay for movies get to see them, they build digital rights management into this standard.

Movie theaters had to spend fortunes to upgrade to "secure" projectors. A single vendor, Deluxe Technicolor, monopolized the packaging of movies into "Digital Cinema Prints" for distribution to these projectors, and they used all kinds of dirty tricks to force distributors to use their services, like arbitrarily flunking third-party DCPs over picky shit like not starting and ending on a black frame.

Over time, the ability to use unencrypted files was stripped away, meaning every DCP needed to be encrypted, and every projector needed to have up-to-date decryption keys. This system broke down on Jan 1, 2024, and cinemas all over the world found they couldn't play Wonka. Many just shut down for the day and refunded their customers:

https://www.theverge.com/2024/1/1/24021915/alamo-drafthouse-outage-sony-projector

The problem? Something that every PKI system has to wrangle: an expired certificate from Deluxe Technicolor. The failure has been dubbed the Y2K24 debacle by projectionists and film-techs, who are furious:

http://www.film-tech.com/vbb/forum/main-forum/34652-the-y2k24-bug-major-digital-outage-today

Making everything worse is that Sony mothballed the division that maintains its projectors, so there's no one who can update them to accommodate Technicolor's workaround. Struggling mom-and-pop theaters are having to junk their systems and replace them. There's plenty of blame to go around, but Sony is definitely the most negligent link in the chain. Shame on them.

Big corporations LARP this performance of competence and seriousness, but they are deeply unserious. This week, I wrote, "we're nowhere near a place where bots can steal your job, we're certainly at the point where your boss can be suckered into firing you and replacing you with a bot that fails at doing your job":

https://pluralistic.net/2024/01/15/passive-income-brainworms/#four-hour-work-week

Score one for team deeply unserious. The multinational delivery company DPD fired its support staff and replaced them with a chatbot. The chatbot can't tell you where your parcels are, but it can be prompt-injected into coming up with profane poems about how badly DPD sucks:

https://twitter.com/ashbeauchamp/status/1748034519104450874

There once was a chatbot named DPD, Who was useless at providing help. It could not track parcels, Or give information on delivery dates, And it could not even tell you when your driver would arrive.

DPD was a waste of time, And a customer's worst nightmare. It was so bad, That people would rather call the depot directly, Than deal with the useless chatbot.

One day, DPD was finally shut down, And everyone rejoiced. Finally, they could get the help they needed, From a real person who knew what they were doing.

This is…the opposite of an AI hallucination? It's AI clarity.

As with all botshit, this kind of AI self-negging is funny and fresh the first time you see it, but just wait until 3,000 people have published their own versions to your social feed. AI novelty regresses to the mean damn quickly.

The old, good web, by contrast, was full of enduring surprises, as the world's weirdest and most delightful mutants filled the early web with every possible variation on every possible interest, expression, argument, and gag. Now, you can search the old, good web with Old'aVista, an Altavista lookalike that searches old pages from "personal websites that used to be hosted on services like Geocities, Angelfire, AOL, Xoom and so on," all ganked from the Internet Archive:

http://oldavista.com/

I miss the old, good internet and the way it let weirdos find each other and get seriously weird with one another. Think of steampunk, a subculture that wove together artists, makers, costumers, fiction writers, and tinkerers in endlessly creative ways. My old pal Roger Wood was the world's most improbable steampunk: he was a gay ex-navy gunner who grew up in a small town in the maritimes but moved to Toronto where he became the world's most accomplished steampunk clockmaker.

I was Roger's neighbour for a decade. He died last year, and I miss him all the time. I was in Toronto in December and saw a few of his last pieces being sold in galleries and I was just skewered on the knowledge that I'd never see him again, never visit his workshop:

https://pluralistic.net/2022/10/16/klockwerks/#craphound

A reader just sent this five-year-old mini documentary about Roger, shot in his wonderful workshop. Watching it made me happy and sad and then happy again:

https://www.youtube.com/watch?v=eqMGomM8yF8

The old, good internet was so great. It was a place where every kind of passion could live. It was a real testament to the power of geeking out together, no matter how often the suits demand that we "stop talking to each other and start buying things":

https://catvalente.substack.com/p/stop-talking-to-each-other-and-start

The world is full of people with weird passions and I love them all, mostly. Learning about Don Bolles's collection of decades' worth of lost pet posters was a moment of pure joy (I just wish more of it was online):

https://ameliatait.substack.com/p/the-man-who-collects-lost-pet-posters

That's the future I was promised: one where every kind of freak can find every other kind of freak. Despite the nipple-deep botshit we wade through online, and the relentless cheapening of words like "innovation" and "future," there are still occasional gleams of the future I want to live in.

Like the researchers who spliced a photosynthesis gene into brewer's yeast (a fungus) and got it to photosynthesize, and to display enhanced fitness:

https://www.cell.com/current-biology/fulltext/S0960-9822(23)01744-X

As Doug Muir writes on Crooked Timber, this is pretty kooky! Fungi – the coolest of the kingdoms! – can't photosynthesize. The idea that you can just add the photosynthesis gene to a thing that can't photosynthesize and have it just kind of work is wild!

https://crookedtimber.org/2024/01/19/occasional-paper-purple-sun-yeast/

As Muir writes: "Animals have no evolutionary history of photosynthesis and aren’t designed for it, but the same is true for yeast. So… no reason this shouldn’t be possible. A photosynthesizing cat? Sure, why not."

Why not indeed?!

OK, that's this week's linkdump done and dusted. It only remains for me to share the news with you that the trolley problem has been finally and comprehensively solved, by [email protected], of the IWW IU 520 (railroad workers):

Slip the switch by flipping it while the trolley's front wheels have passed through, but before the back wheels do. This will cause a controlled derailment bringing the trolley to a safe halt.

https://kolektiva.social/@sidereal/111779015415697244

I'm Kickstarting the audiobook for The Bezzle, the sequel to Red Team Blues, narrated by @wilwheaton! You can pre-order the audiobook and ebook, DRM free, as well as the hardcover, signed or unsigned. There's also bundles with Red Team Blues in ebook, audio or paperback.

If you'd like an essay-formatted version of this post to read or share, here's a link to it on pluralistic.net, my surveillance-free, ad-free, tracker-free blog:

https://pluralistic.net/2024/01/20/melange/#i-have-heard-the-mermaids-singing

120 notes · View notes

elderflowergin · 7 months ago

Text

blood free v secret forest, a quick and dirty comparison:-

As someone who fell for Kdrama through Stranger, i loved it because it appeared seamless, grounded and weaved several systems and levels of privilege very elegantly. Most of all it seemed morally urgent, even if it was at its core a detective mystery. (Which, to be fair, Blood Free is as well.)

Secret Forest’s first success was that it held nuance for everyone in the middle of the road; LSY afforded so much thoughtful shading to those men. I often think they will never look as beautiful as they do on SF, and that’s only partly because of whoever did the lighting etc, but they’re not Kdrama glossy perfect; they’re real people trying to reckon with themselves and the moral calculus they have agreed to, and their dignity comes from the reckoning. Lee Chang-joon, Kang Won-chul, Lee Yeon-jae, even Seo Dong-jae for that matter, all have that advantage. LSY managed this for Jung Sung-il in the scant few minutes of screen time he had.

The second success was Cho Seung-woo and Bae Doona. If Secret Forest was a universe they were its gravitational field; it was their fierce sense of honour and morality that drives both seasons. And their moral decency is hard-won; it is tested constantly, and it’s burnished at each opportunity, which is why they are respected. It is a dream that people like that can influence or impact those around them, but you don’t question that they do, by the end of each season, and that’s the victory of writing, casting and the charisma of both leads.

That’s why that funeral scene in season 1 is so important (to me); it shows the gravity shifting. The prosecutors rely on their forest of secrets to keep the centre together, but Hwang Si-mok demonstrates how untenable this has become, how the roots must be pulled out so the weeds die; so new healthy things can grow. The chaebols are at the periphery, and they continue to be there because, most audaciously of all, they don’t matter if enough people shift their moral calculus. I think this gravitational pull happens to Lee Chang-joon in season 1 thanks to Hwang Si-mok and it happens to Choi Bit in season 2 thanks to Han Yeo-jin. They are easily some of the most powerful parts of the show.

On the other hand, we have Blood Free. I’m not sure who the moral gravitational field of this show is meant to be. Maybe it’s Yun Ja-yu and/or Woo Chae-woon. Maybe it’s Lee Mu-saeng. Maybe it’s about the ethical dilemma of experimentation and whether that’s a worthwhile price to pay for the scientific advancements in cultured meat and seafood. Perhaps we need more time to really see the middle of the road characters, but four episodes in there’s not much to go on: there’s Lee Mu-saeng, there’s Queen Dowager as a VP, here’s Jeon Seok-ho. There are three chaebols, all of whom seem like one-note characters to me. (Why ask a talented sketch artist to produce cartoons like these? Unless they’re not, but nothing seems to suggest otherwise.)

The most interesting insight from episode 4 was about Yun Jayu - when offered 72 trillion won for her company, she actually considers it because it means she doesn’t have to face investors and can focus on research. She has influence and money but these are means to an end, for her. I wish we could see more of that, and not necessarily through exposition alone.

When she gives deft, cool answers to reporters, did that come naturally to her or did she work at it? Is she the face of the company because she hated it a little less than Lee Mu-saeng did? If so, why? What comparative advantage did they determine she had? When she wears Chanel tweed skirts and smiles her way through presentations, is that a natural extension of her work or is that a mask she wears? Give me process, guys! Give us the backstory, the way the markets work, the environment for cutting-edge bio research in Korea, the reaction of Big Meat, the interplay of new rich and old rich, some indication of her actual influence (which must be considerably more than what we see on the show, although what little we see, while uncomfortable, is frankly not that inconceivable in a world where you’re constantly connected.) I am so interested in her, and yet I feel I am made to watch the story of her reacting to chaebols and to the mystery of corporate sabotage rather than her being the fulcrum of her own universe. And at no point does the mystery seem morally urgent to me, and it’s because 1) why does it matter if all this is is a giant M&A negotiation 2) why should we care if it doesn’t feel real to us? So what if there’s sabotage? Why on earth isn’t this company guarded like fucking Fort Knox? Why is this company ostensibly so influential, so powerful and yet capable of unusually amateurish errors that are the centre of the show so far and not on the periphery of it? Where is the moral quandary that is meant to grab us by the throat?

Is it a question of the writing? Have her interests shifted and did she want to do a show without having to do too much character work? If anyone has earned a vibes-only moment it’s Lee Soo-yeon, and I respect that for her. I hope the direction isn’t stifling the writing, because that means there is an arresting, politically trenchant drama underneath this dry procedural, and that’s upsetting to consider. We still have a ways to go and I think there is potential, but I have to remind myself not to expect something like SF, that maybe you can’t bottle that formula. That it’s the gold standard for a reason. But honestly, Disney, in the words of TikTok star imo_unusual, you’ve made this show like God was dozing off when the angels were working, now RELEASE US (and LSY writernim)

#sorry i didn’t finish life #and I didn’t include grid in the analysis #although that’s a good comparison to make too #but kudos to whoever costumed hhj #and gave her that expensive overcoat #that looks exactly like a doctor’s coat but in rich black #costuming is the only dept that has not been interfered with #blood free #tvn stranger

32 notes · View notes

phantomdoofer · 3 days ago

Text

Tower Town, Chapter 24 - Betrayal

Content warning for graphic descriptions of death and bodily harm.

Paolo sat back. “Wow. You two were that close?”

Aldo sighed deeply. “Thick as thieves, as the old saying goes. At least, I thought we were.” He stared into the distance.

Paolo waited, but the old gnome seemed to be lost in memories. Finally, he coughed, and Aldo shook his head. “Sorry, ragazzo. Where were we?”

“You had just been roped into conspiring with your department head,” Paolo said with a wicked grin.

Aldo laughed. “You make it sound so skullduggerous! You have to admit, we had our reasons. Anyway, the next couple of years didn't involve anything of real importance - exciting if you were a researcher, not so much to anyone else. But a couple of years down the line, things got much more interesting…”

~~~~

Raphael slammed his hand down on the counter, sending pens and tools bouncing to the floor. “No, Dom! I refuse to try to… to market this to anyone! Remember, we agreed - this was too dangerous to release like that! It could destroy the world!”

Dom flung his hands up in frustration. “Why are you being so damn thick-headed about this, you arrogant rock! I told you, there's ways to put fail-safes in our work! We could even remotely destroy them!”

“Yeah! By blowing them up,” Raphael said hotly. “you don't think that might be just a touch inhumane? To say nothing of someone getting their hands on that little toggle and blowing your precious army into chunky salsa!” He shook his head violently, but his voice dropped a bit. “No, Dom. It's too dangerous. Too easy to fuck up.”

Dom stared at him silently. Finally, he snorted. “Well, I guess the great Raphael has spoken, hasn't he? It's his work, after all, I have no say in it…”

“Oh, come on, Dom, it's not like that and you know it,” Raphael said, his voice rising a little again. “I didn't get into this to profit! I did it to help people! I thought - I thought you felt the same,” he finished quietly.

Dominic's eyes softened a bit. “I did, of course. But… in all seriousness… do you really think we can keep this genie in the bottle? Once it's out, it's out. It'll be a new arms race, maybe the worst in history. There's definitely gonna be people with no scruples about selling this tech once we release it. Why shouldn't we profit off it?”

Raphael's heart sank. There was too much truth in Dom's words. He turned and put a hand on the computer beside him. “You're… you're right about that.” He stared at the screen, window into his life's work, a single page of the hours and days and years the two of them had poured into it. His blood was in this research. Literally. “Maybe we should just erase the whole damn thing. Forget it ever existed,” he whispered.

Dom’s eyes almost popped off his face. “B-buh-but,” he spluttered, “all our work! All our time and effort! Raph, Raph, don't be hasty…” he was practically vibrating with stress and fear.

“I know, Dom,” Raphael said sadly. “But… I've been thinking for a while. This is so dangerous. And you make a good point. There are people out there who will murder the world just to make a profit off this.” He leaned back. “‘At the end of the world, the last man will murder his brother in cold blood. And ascending a mountain of skulls, he will sit down and declare triumphantly, ‘I won!’”

Dom blinked. “What's that from?”

Raphael shook his head. “I don't remember where I read it. It's old, ancient, even. But it's always stuck with me.” He hopped down, walking slowly to the door. “Maybe we won't be helping the world. Maybe we'll just be putting the gun to our heads.”

Dom stood in complete silence as Raphael closed the door behind him.

~~~~

Raphael squinted as he walked out into the sunlight. He held up a hand, shielding his eyes. How long has it been since I came outside?

The sights of modern Rome were a carefully-crafted mix of cutting-edge technology and ancient style. Rome was one of the few cities to retain its identity all these millenia.

It was also one of the few cities to survive the Scorched Earth era.

Some of his colleagues waved and called to him. He waved back, and one in particular caught his eye. “Hey, Gia!”

The younger gnome ran over, flipping her hair out of her eyes. “Doctor Alighieri! It's been years! How are you?”

He blushed. He'd had quite the crush on this woman, years ago. “Oh, I've been so caught up in what I was doing, I just…”

She laughed. “Lost track of time. It happens to the best of us, Doctor!”

He smiled. “Just call me Raphael, Gia. Or Raph, if you like.” He waggled his eyebrows suggestively.

She giggled and playfully slapped his shoulder. “Doctor! We're in professional environs! We shouldn't be so familiar!”

He lowered his voice. “Perhaps we could meet under… less professional circumstances? Say, this evening at eight?”

She eyed him speculatively, but she seemed interested. Her friends were whispering to each other. Raphael was one of the top researchers there, and it wouldn't hurt her at all to be seen in such prestigious company, even if it was casual. “All right then. Eight o’ clock, sharp, Doctor. Right here.”

“I'll wait with baited breath…” he paused, in the middle of a formal bow to kiss her hand. “By the way, what is you title now, Gia? I know you haven't just been resting on your laurels all this time.”

She chuckled. “It's ‘Doctor’ as well, now, Doctor. Doctor Giovanna Hulbrew.”

He stood and switched to shaking her hand. “Congratulations, Doctor! I'd love to discuss your research over dinner… along with yourself.” He quickly lifted her hand to his lips and kissed it before she could retract it.

She laughed. “You haven't changed at all, Doctor!” Then she smiled brightly. “I'm glad. I was afraid being cooped up with Doctor Totino would sour you.”

“Oh, he's not so bad,” he said airily. But his mind drifted to darker interpretations. What has he been up to to earn such a reputation?

She gave Raphael a searching look. “If you say so, Doctor. Eight o’ Clock!” She waved to him over her shoulder as she sauntered away.

Raphael squared his shoulders. He was in a much better mood, now.

He walked off into the parklands around the Institute, whistling a jaunty tune.

~~~~

Raphael woke up, snorting as he did. The sunlight through the apartment window had woken him. So unused to that.

He looked over. Gia was burrowed into her pillow, snoring softly.

He smiled and gently kissed her forehead. Apparently she'd missed him as much as he'd missed her. They'd come back to her place for the night, and things had proceeded from there.

He stretched and yawned. I needed that - getting out of that lab. They'd chatted all through the evening - he'd had to be vague about his own research, of course - but she'd been happy to share her own work.

He'd hung on every word. He loved knowledge as much as he loved women, and here was both in a single package.

He quietly snuck out of the bed, sliding into his clothes. He didn't want to sneak out, but he also didn't want to wake her. He'd figured out that she was on the verge of exhaustion herself, and had coaxed her to take the day off. When she'd protested, he'd pulled some strings to get Testa to agree to it.

“No, no, I agree. Doctor Hulbrew, you're no good to us burnt out and exhausted. Take a day off.”

And so she had.

As he buckled his pants, he heard her stir behind him. “Mmm, leaving already?” She said sleepily.

He turned, grinning over his shoulder. “Duty calls, and all that. I really enjoyed last night.”

She smiled. “I missed you, too. My neighbors might not have.”

He blushed a little. “I meant the dinner conversation, but that was nice, too.” He laughed. “We need to get together and compare notes sometime.” He rolled his shoulder. “Not today, though. You get some rest, some real rest.”

“She laid back, saluting jauntily. “Yes, sir, Doctor Alighieri.” Then she yawned. “Call me, OK? I know you don't have much free time.”

He nodded. “I will.”

And he meant it.

~~~~

Raphael stood, staring at the Institute's gleaming Tower… and felt a massive sense of dread, like a lead weight, settle into his soul. I don't think I'm ready to go back, yet. But what to do?

His entire life revolved around the place, now. He didn't even have separate living accommodations - he slept in the lab.

He looked down at his hands. When did I sacrifice my life to this?

He couldn't recall.

He turned, walking away. Testa gave me time. I'm gonna take it.

~~~~

Raphael was sitting at a street cafe, munching on a plate of tacos. The Institute had a robust cafeteria, of course, but…

It can't replicate the experience.

Around him, people chattered about nothing in particular, laughed, smiled, yelling and crying and living. The full experience. It was like sitting in the middle of a maelstrom, and he found his heart aching with a mixture of joy and exasperation.

I should have done this a long time ago.

He felt his phone buzz. He sighed and pulled it out.

Where are you, Raph?

Dom, Raphael thought. Fair. This is pretty out-of-character for the me he's used to. He typed out a reply:

Sorry Dom, my burnout got too bad, Testa sent me on a trip Outside. Just out mingling and relaxing. Something wrong?

He'd barely sent the message when he got the reply.

Oh, OK. Just used to you being in the lab. On that grind, you know? You get your head back on the right way, Raph. Probably do you good.

Raphael nodded to himself. He was feeling better. The feel of fresh air on his face, the sound of birds, the chatter of the people… it was reminding him of why he was doing what he was.

The whole point is to improve the world.

He checked his credit account - he was well in pocket. The Institute gave him a generous stipend he rarely used. By most people's standards, he would be almost rich.

Think I can afford to take a few days.

He sent back - Think I'm going to take some time coming back. Freshen up my view, stuff like that. You OK being alone for a few days? Remember, you can call Testa if you have a problem.

He had enough time to finish his meal before the reply came.

All right Raph, I'll hold things down here. I shouldn't need Testa's help, but I'll keep him in mind. Any idea how long you'll be gone?

Raphael put a hand to his chin, stroking his beard. How long, indeed?

Until I feel better.

Don't know, friend, he sent back. Until I feel inspired to work on it again, I suppose. I'll try not to be more than a week.

All right. It'll be here when you get back. Maybe better.

Raphael chuckled - he could see the smug little smirk on Dom's face in his head.

He flipped apps and quickly found a little hotel to stay in that had an “indefinite” option. He booked it for immediate use, then locked his phone. He looked around, taking in the sights.

Time to reconnect with life outside the Institute.

~~~~

Raphael walked through the main doors a week later, whistling. He'd been to concerts, visited bookstores and old friends and more restaurants than he could recall. Why have I been denying myself this? He'd attended one of Gia’s lectures, and it had reconfirmed his love for the woman. She was just as smart as she was beautiful. He'd even sat down one day and helped her work past a thorny problem in her own research.

“Can't believe I didn't see that,” Gia had said, exasperated at how quickly he'd seen the issue.

“A fresh perspective can really help,” he'd said. “Outside eyes see differently.”

Now, he felt energized, awake, alive, again. I don't feel like a zombie, anymore.

One of his colleagues walked up, looking concerned.

“What's up?” Raphael said.

The young ogre was at the head of a small group of junior researchers, and they all looked worried. “Dr. Alighieri, so glad you're back. I understand you needed some time to recharge, but…” he trailed off.

After a few moments, Raphael rolled his hand and quirked an eyebrow. “Buuuuut…?” He said leadingly. Sometimes these kids need some encouragement to say what they're thinking.

The young ogre scratched absent-mindedly at the patchy beard that was so common on young male Ogres. “You know, your work partner, Doctor Totino? He hasn't been seen outside your lab the whole time you were gone.”

Raphael smirked. “And that's unusual?”

“It really is,” he said. “No offense, sir, but it's usually you who stays in the lab. Doctor Totino is usually the one out grabbing things, interacting, being seen. It's been a little off-putting.”

Raphael blinked, realizing what the younger researcher said was 100% true. It IS usually me cooped up in there. “Is he at least getting food sent in?”

“Not as much as he should, no,” the ogre said. “He keeps the door locked. Even Director Testa is getting concerned. He only let the Director in once, just to show he was OK.”

Dom, what have you been doing? “I'm sure he's just been really focused,” Raphael said, waving a reassuring hand at the small, worried group. “He can get that way, sometimes. Couldn't tell you how many times I've made him stop and eat, or take a nap. Man gets focused, he won't stop til he falls over.” He laughed lightly, and the group followed suit, even if it was a little stilted. “Don't worry, guys. I'll check on him. And I'll let him know you were concerned.”

“Thank you, Doctor,” he said. As the rest of the group broke up, he paused. “Sir, if I may ask a question…”

Raphael planted his feet. “Shoot. I'll answer if I can.”

“What are you two working on that's got you both so focused?” He said hurriedly. “You even have Director Testa helping you!”

Raphael sighed and laughed ruefully. “Ah, lad. Can't answer that. Not yet. Don't worry, once we get finished, you'll know.” He paused, his eyes a bit unfocused, and looked upwards. “The whole world will know.”

The Ogre seems a bit taken back at the statement. “Well, I know if you're involved, sir, it'll be something big.”

Raphael came back from his thoughts and smirked at the young Ogre. “You trying to butter me up, young man?”

The Ogre quickly held his hands in front of him, looking contrite. “Oh, no sir! Nothing like that! It's just… you're an inspiration, sir. To a lot of us, down here on the ground. You're so much more approachable than the others. We all wish you'd come out more. You make us feel like we're part of something big.”

Raphael reached up and patted the Ogre's hip. “You are part of something big, ragazzo. The things we do here are important. Not just for us. Remember that. You may be just one cog, but this machine changes the world.”

The young man smiled. “That's what I'm talking about, sir. You make us feel appreciated. Special.” He squared his shoulders. “I've taken enough of your time, sir. Thanks again!”

Raphael waved as the young man walked away. Good kid. We need people like him.

An elevator opened, and Director Testa stepped out. “Ah. Raphael, my boy. Glad you're back. Your colleague has had some… concerning behaviors since you left…”

Raphael nodded. “Yeah, the kids just clued me in. No idea, sir. Dom has been dead silent since I told him what I was doing. I was just about to go upstairs and find out, myself. Care to come along?”

Testa nodded, and they walked into the elevator. “He admitted me once, but it was a brief visit. I didn't see anything untoward, but… he was so nervous.”

“He's always nervous,” Raphael quipped.

“True. But something felt… off. I didn't want to alarm him, so I left it alone, but…” he sighed. “I would really like to know what's going on that's got him so worked up.”

The door dinged and opened, arriving at the floor where their lab resided. “Like I said, he's been dead silent the whole time. We'll find out.” He pulled out his keycard, flashed it at the reader… and it made a negative noise, indicating the door was passcode-locked. “Strange,” he said, entering a code, only to be rejected. “He never puts this level of lock on the door.”

After several failed attempts, Raphael had gone from concerned to annoyed. “I apologize for this, Director,” he said, and his eyes lit on fire. He held a hand up to the screen…

Lines of fire wove through the circuitry of the lock, striking like serpents at key points, physically breaking down the machinery keeping the door locked...

The lock made a positive beep, and the lock opened.

“That's a handy trick,” Testa said.

Raphael’s eyes returned to normal. “Yeah. But now we need a new lock.” He waved his key again, and the door opened.

Inside was dark, only the lights of the computers and equipment lighting the room. A smell of chemicals and stale bread wafted out of the room - the smell of a Ninda who wasn't taking care of themselves.

Raphael and Testa walked through the door, which whooshed closed behind them. “Dom?” Raphael called out. “Is something wrong? You OK?”

“I forgot you said you'd be back by now,” Dominic's voice called from the shadows. The Ninda appeared from another room.

Raphael approached him. “Mio Dio, amico, you look rough. You've been neglecting yourself again.”

“Oh nothing of the sort,” Dominic said airily. “I've made some major improvements since you left, in fact.”

“Improvements?” Raphael said in surprise. We didn't talk about doing any major changes! “Can't wait to see what you've been up to, Dom, but…”

Testa stepped forward. “I and your colleagues have been worried about you, Doctor Totino. You haven't been seen in over a week, other than my brief visit. You're normally more… out and about. If I may ask, what have you been doing in here to keep you so cloistered?”

Dom immediately got defensive. “I told you, I've made some major changes. Is that so wrong? People need to mind their business!” His face turned red as his temper grew.

Raphael held up a hand in a placating gesture. “Dom, no one's making any accusations! They're just worried about you, is all. You know how we can get… a little hyperfocused at times. We try to look out for each other, you know?”

“What business is it of theirs?” Dominic said, swiping the air with his hand. “They just want to steal my work!” He pointed a finger at Testa. “Just like you!”

Raphael felt his own temper rising. “Dom! No! You're being paranoid! Testa's trying to help! We never would have gotten this far without him!”

Testa stepped forward. “I don't appreciate your words, Doctor Totino. I've been thinking for a while now - maybe you need to take some time for yourself, get out of this place. It seems to be wearing on your nerves.”

“NO!” Dominic roared. “You’re not gonna steal my work out from under me!”

“No one's suggesting that, Dom!” Raphael said. “Also, ‘your work'? This is our work, Dom! Ours! Together! I brought you in on it because I knew you would be able to help! But you're acting like it's all yours, now!” A note of despair crept into his voice. “ I'm sorry, Dom, but… maybe you should step back for a while. Go get your head back on straight.”

Dom looked stunned. “You're… kicking me out, Raph?”

Raphael felt his heart break a little at the pain in his friend's voice. “Dom, I… I don't think you're doing well. In your head. You've changed, man. It's affecting your judgment. The old you wouldn't have jumped all over the Director like that. What's wrong, buddy?”

Dom was looking at the floor. “You don't want me here, anymore. I get it.” The air seemed to shift. “You want all the glory for yourself. The great Raphael Alighieri, the famous, talented researcher, savior of the world.”

“Dom, it's not like that…”

“You were always better than me. Lording over me. Making me feel inferior.”

Raphael's eyes went wide. “No, Dom, I never-”

“Shut up, Alighieri.” The venom in Dominic's voice brought Raphael up short. “I'm done with you. Done with you both.”

He snapped his fingers.

Suddenly Raphael and Testa were floating in the air. A swirling aura of white flame surrounded them, holding them up.

Raphael stared in horror. That's my flame. “Dom… Dom, what have you done?”

Dominic looked up, and the smile on the Ninda’s face was dripping with malice. “I'm doing what I always planned to do, ‘old friend,’ ever since I saw what your power was capable of.”

Testa writhed beside him in the air. “Let us go, Totino! What do you-”

Dominic snapped his fingers, and Testa began to burn from the inside out. The man shrieked in agony as his innards boiled and his skin crisped. Raphael tried not to vomit as the charnel smell flooded the room. He tried not to think about the sound of the man's fluids bubbling and popping… but the sound burned itself into his mind.

Shortly, nothing but ash remained.

“I never liked him, anyway,” Dom said casually.

Raphael stared. He couldn't believe it. “Dom… why…?” He said in a tiny voice.

Dominic scoffed. “You had me genuinely worried for a moment, ‘old friend,’” Dom said. “I really thought you would destroy all that work you did.” He gestured, and Raphael drifted closer.

Outside, the sound of people beating on the door were audible. Testa had not gone to his death quietly.

“But you made a fatal mistake,” he said, smiling, “when you left me alone with it. With the password, no less.” He laughed. “That gave me plenty of time to copy everything over to my own private archive… and to take a few other steps.”

Raphael saw the door fly open, and several of their colleagues stood outside. “My God, what -” one started.

Without looking, Dominic sent a wash of white-hot flame into the corridor.

The screams were barely audible over the roar of flame.

Raphael felt tears trying to drip down his face, but they evaporated nearly instantly. “Was I just… a means to an end, for you?” He said, his own eyes lighting up -

The wall of flames pulled in closer; Raphael smelled his beard and hair starting to burn. “Ah ah ah,” Dom said, waggling a finger. “I know all about how your power works, Raphael. More than you do, in fact. No, I genuinely liked you, once.” He laughed. “You sweet, gullible little fool. You could have ruled the world. Even before your admittedly brilliant research.” He nodded. “I never would have figured out some of what you did. Thank you for that - you made this so easy.”

Raphael felt his own eyes beginning to sizzle as the flames burned him. “What… are you going… to do…?”

“Isn't it obvious? You were right - this is too dangerous to let run loose. So… I'll just… keep it to myself.” He chuckled malevolently. “I'll take every other power in the world for myself, too. Then it won't be a problem, will it? And I'll just rule everything. Can't be wars between nations if there's only one, right?”

Raphael didn't think he could get any more horrified. He was wrong. “No…”

“Oh yes.”

A spear of white flame pierced Raphael's heart. He gasped as he felt his organs flash into ash. He barely felt it as he slammed to the ground.

He could barely see Dom bend over him. “As thanks, I'm granting you a quick death, old friend. You won't be here to see me take over this tainted world… but you can watch from the other side, and think… this is all my fault.”

Dom turned and started to walk through the gaping, melted hole where the door had been. Raphael weakly raised a hand. “N-no… please…” he whispered…

Then there was nothing.

~~~~

Hours later, the small, charred body laid where it had fallen. The room was silent, except for the occasional beep of a computer.

A tiny white ember appeared in the hole in the corpse's chest.

It quickly grew, tendrils of flame reaching out and wrapping around the body. A mesh of flame wove inside the gaping cavity that had been Raphael's torso.

The flesh began to knit.

Raphael's body began to hover in the air, surrounded in a cocoon of flame.

After a few seconds, his eyes flew open as his mind was violently reawakened. He gasped, then shrieked as half-restored nerves screamed damage reports to his brain.

The pain was indescribable.

He looked down, watching as the blackened flesh writhed, becoming whole and pink again. He sobbed as his overloaded mind tried to comprehend what he was seeing.

Behind him, a pair of huge flame wings sprouted from his back.

Finally, restored to his healthy form, the flames faded, and he dropped heavily to the floor. He stayed on all fours, gasping and sobbing as the pain slowly faded.

The memory of his friend's betrayal was almost as bad.

Shakily, he stood up, holding a hand up to his face. He turned it, examining both faces. The flesh was warm, whole, unblemished. He patted his chest, and realized his shirt had completely burned away. He stared down at his breastbone. There isn't even a scar.

As his mind settled, he realized what had happened. My powers resurrected me.

He staggered out through the melted hole where the door had been… into a nightmare. Most of the lights were broken, and piles of ash lay everywhere… if the half-burned body wasn't laminated to the wall, or in one case, the ceiling. As he approached, the vibrations of his steps caused the body to break loose, and it fell to the floor, bursting into a grotesque amalgam of half-cooked flesh, charred bone, and ashes.

Raphael would have vomited… if he'd had anything in his stomach to pass.

He retreated back to the remains of his lab. He seems to have left it mostly untouched. He growled. Obviously a ‘mercy’ for his ‘old friend’. He was surprised to discover the computer still worked, and even had network access. He pulled up a map of the building…

Most of it was darkened. Offline. Such a simple word for what's been done. He used codes and hacks he'd never told anyone he had, not even Testa or Dominic, to access the cameras. He stared, appalled, for a few moments, then he shut them off. The scene was the same everywhere. He left no survivors. Except me… and that was accidental.

Another kind of flame was building in his chest, now. You're gonna pay for this, Dominic.

He accessed their research database, and found it scoured. No real shock, here. Dom wasn't stupid. He’d known their research could be used against him, and taken precautions.

Raphael smiled grimly. Not enough, though.

He walked over to a nondescript part of the wall, tapping a specific sequence in ancient Morse Code. Part of the wall swung out, revealing a hidden alcove. Testa had helped him set this up, months before. He glanced over at the sad pile of ash that had been his mentor and friend. Thank you, for everything you did.

He reached in and pulled out a high-density storage drive. It had everything they'd ever done. He pocketed it. Probably gonna need this in the near future.

He ran over to the stairwell - he already knew the elevators wouldn't be working. He looked down the endless flights, feeling his heart sink. Gonna take me forever to get down there.

Then he came up with a solution.

He leapt over the guardrail, in free fall. As he approached the bottom, he fired off a flame blast, slowing his fall...

It wasn't enough, though, and he landed hard. He heard a sickening crunch as his legs broke.

He rolled over, screaming, the pain blinding him… and then he screamed louder as he felt his body light on fire again, and the bones and flesh violently realigned and healed.

In seconds, it was like nothing had happened.

Raphael sobbed, standing shakily, covered in sweat. Great idea, Raph, he thought. Just slow yourself down, that'll work great…

He walked out into the lobby. It was the same as everywhere else - ash and laminated bodies. The entire front wall was gone, blown away.

He stepped outside…

He stood and stared at the destruction. Dominic had apparently gone on a destructive rampage on his way out. Buildings were either blown to bits, half-melted, or collapsed.

And bodies. Everywhere, scorched, blackened bodies. Ash flaked off them in the wind. Trees and grass were either scorched stumps or just completely gone. The vista had been a mix of natural beauty and inspired architecture, before. Now, everything was silent. Not a bird sang. No insects buzzed. A malevolent firestorm had razed the entire city.

It was the aftermath of an apocalypse.

Raphael used his flame to fly upwards. It was shaky, but he had better control this time. He found more of the same. Buildings, plants, animals, people…

Complete genocide.

Raphael thought about the eager young researchers, happy and excited to be part of something bigger.

He thought of all the people he'd met in his wandering, just going about their lives… unaware of the horrors to come.

Horrors that I enabled.

He thought of Gia, and he spun, flying over, looking for her apartment… and saw only a blackened mound of slag.

He circled the whole city, looking for any sign of life. The silence was deafening.

An hour later, he hovered, dejected. Everyone and everything was dead or destroyed. He landed, looking around in despair at the destruction surrounding him, his eyes full of tears. This is my fault. My hubris. My blindness. My trust. Cost all these people their lives.

He clenched his fist. I will fix this. If it takes me eternity, I'll fix it.

~~~~

Paolo sat back, horrified at what Aldo had told him. “My… my God…”

Aldo nodded. “Yeah. While I'd been gone, Dom gave himself a copy of my power. Then, when I said what I said to him… I guess that was the final straw.” Aldo sniffed. “He razed Rome. I can still smell it. People came back, but… it wasn't the same.”

“And you spent the next 500 years fighting him?” Paolo said, his voice shaking.

“Yep. Started using the name “Nascosto” to hide my identity. Started the Resistance. Started engineering powers to give to people I thought could handle them.” He clenched his fist. “And I started trying to work out a way to stop him. I couldn't figure out a way to kill him permanently, then, but…”

“But you came up with a way to stop him. That ring,” Paolo said.

“Yeah. It took four of us - the strongest members of the Resistance - to do it.” Aldo growled. “And the sick bastard still got us with the Plague.”

“It worked out in the end, though,” Paolo said, grinning.

“Yeah. Yeah, it did,” Aldo said, a smile growing on his face. “Thanks to you guys.” He hopped out of the chair.

Paolo stood, facing him. “Thanks, old man. Thanks for letting me know… we were right to do what we did. And thank you… for giving us the chance.” He laughed. “And thanks for coming to visit.”

Aldo chuckled. “Anytime, ragazzo.” He turned, then turned back. “I know… I know you worry that you're like him. And to be fair, as someone who knew him… you do have a bit of him.”

Paolo felt his blood run cold.

“But you need to remember - that sick, cold feeling you got, just now? That shows you're not him. You're better than him. You care.”

“How… how did you know?” Paolo whispered.

“It was written all over your face, lad,” Aldo said. “Three thousand years of experience? You learn to read people.” He walked back, grasping Paolo’s arm. “Keep that in your head. Right now, you're better than him. No matter what happens, no matter where you end up… you did the right thing, in the end.”

As the old gnome left, Paolo slumped onto the bed. I'm better than he was.

Paolo held those words close, and they warmed his spirit.

6 notes · View notes

annamelia-art · 1 year ago

Text

November 14th is World Diabetes Day!

I'm someone who works with people affected by (mainly type 1) diabetes and I want to raise some awareness of positive things happening in 2023!

(Please note, I'm from the UK, so I'm biased to a UK perspective, and we are a bit behind some of the rest of the world...)

Best news is that the recent draft NICE guidance has recommended hybrid closed loop for people with type 1 diabetes. 🎉

Did you know that currently there are multiple hybrid closed loop insulin pumps on the market? These operate as close to the pancreas as we are currently able to mimic (a continuous glucose monitor measures interstitial fluid glucose and adjusts insulin delivery from a continuous subcutaneous insulin infusion pump - all the person has to do is tell it how many carbs they're eating, and the algorithm does the rest)

Have you heard about the ELSA study? This is screening for children happening right now in the UK to identify if they are at risk of developing type 1 diabetes. It requires only a simple finger stick blood glucose test and is open to every child aged 3 - 13, living in England, Scotland, Wales and Northern Ireland.

How about Ogluo? It's a newer form of glucagon that can be used like an EpiPen, which is a lot easier than the orange box for a panicking parent!

I'm going to reblog with some links to information about World Diabetes Day and charities that support research into diabetes (type 1 and type 2 and rarer types).

#diabetes #world diabetes day #type 1 diabetes #type 2 diabetes #elsa study #hybrid closed loop #disability #chronic illness

7 notes · View notes

samira-kehmet · 1 year ago

Text

CHARACTER DEVELOPMENT CHALLENGE 8: WHAT IF

What If Samira Decided Not to Become A Doctor?

Alternate life path: Instead of steering away from her family’s greedy pharmaceutical empire, Samira was successfully brainwashed by her father to instead join it. She ended up inheriting the company - not directly from her father but through shady means.

After her father passed away, she received word that her siblings were plotting her demise after it was revealed she would be given most of their parents’ inheritance. She in turn acted quickly and had them all killed before they had a chance.

She then usurped the company, which was immediately challenged by other members of the Kehmet family as she was not a Kehmet by blood.

Any Kehmet family members who attempted to take action either mysteriously passed away or got into serious accidents, until eventually she stopped being challenged.

She married a member of another elite Kraysha family, though it was more of a marriage for business opportunities and not about love. She continued this pattern each time a wife passed away. She had a total of three wives over her lifetime.

Kehmet Holdings began to partake in unethical experiments to more quickly put new products on the market. Prices on drugs also increased substantially to the point where often only the elite on Kraysha could afford many of the widely used medications. This had a huge impact on the quality of life on Erkuss and hybrids of lower classes on Kraysha.

Kehmet Holdings grew so largely that they were able to get away with the above because Samira had successfully absorbed competing pharmaceutical companies until Kehmet Holdings was the one left standing.

Similar to her parents, she paid high sums of money to have Djayyar children of her own whom she could shape into taking over the company, thereby guaranteeing Kehmet Holdings would continue to be run by Djayyar for the foreseeable future.

She still maintained her passion for collecting more knowledge on the Djayyar, and did so by pouring in large sums of money into a research facility and offering money to Djayyar willing to be screened and tested on (with NDAs signed of course).

After her passing, the cycle would continue with her children, and their children, and so forth.

#i realized i never did this for her so here we go #my brain said 'let's mix game of thrones with succession #aop character development #murder tw

3 notes · View notes

bloodcanceruncensored · 1 year ago

Text

Market Research on Car T Therapy--a paid study for USA residents from Health Union

This opportunity was sent to us by our friends at Social Health Network Blood-Cancer.com is conducting a market research study on behalf of a sponsor, to understand the treatment experiences of blood cancer patients who have received or discussed CAR T therapy. If you complete the screening survey and qualify for the study, you may be asked to participate in a 30-minute interview, which would be…

View On WordPress

#blood cancer #Car T

3 notes · View notes

latestmarketresearchreportsblog · 2 days ago

Text

Cell Analysis Market Growth Forecast: Surpassing USD 38.4 Billion by 2030 with a CAGR of 10.4%

Cell Analysis Market: Trends, Growth, and Future Prospects

The Cell Analysis Market, a vital component of life sciences research and clinical diagnostics, was valued at USD 19.2 billion in 2023 and is projected to exceed USD 38.4 billion by 2030. Growing at an impressive compound annual growth rate (CAGR) of 10.4% from 2024 to 2030, the market is poised for significant expansion driven by advancements in technology, rising demand for personalized medicine, and increasing investments in pharmaceutical and biotech research.

Understanding Cell Analysis

Cell analysis refers to the comprehensive study of cells, including their physiological and biological properties. Techniques in this field are used to understand cell function, identify cell characteristics, and analyze cellular mechanisms. It is a crucial tool in various applications such as cancer research, drug discovery, immunology, and stem cell research.

Click Here to Access a Free Sample Report of the Report @ https://intentmarketresearch.com/request-sample/cell-analysis-market-3147.html

Key Drivers of the Cell Analysis Market

1. Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is a major factor driving the demand for cell analysis. Accurate cell analysis is essential in diagnosing these conditions, understanding disease progression, and developing targeted therapies.

2. Growth of Personalized Medicine

The shift towards personalized medicine, which focuses on customized treatments based on individual genetic profiles, is boosting the need for advanced cell analysis techniques. Personalized approaches require detailed cellular analysis to tailor therapies effectively.

3. Technological Advancements in Cell Analysis

The rapid development of advanced technologies such as flow cytometry, high-content screening, and next-generation sequencing (NGS) is transforming the cell analysis landscape. These innovations provide more accurate, efficient, and comprehensive insights into cellular functions, enhancing research and clinical applications.

4. Increasing Investment in Pharmaceutical and Biotech Research

Pharmaceutical companies and research institutions are heavily investing in drug discovery and development, driving the need for robust cell analysis methods. The use of cell-based assays in preclinical studies helps in evaluating drug efficacy and safety, thereby accelerating the research process.

Browse Complete Summary and Table of Content @ https://intentmarketresearch.com/latest-reports/cell-analysis-market-3147.html

Market Segmentation of Cell Analysis

1. By Product Type

Instruments: This includes equipment such as flow cytometers, microscopes, and cell counters. Instruments are essential for conducting various cell analysis techniques in research and clinical settings.

Reagents & Consumables: These are necessary for preparing samples and conducting assays. The recurring demand for consumables makes this segment a significant contributor to market growth.

Software: Advanced software solutions are used for data analysis, image processing, and managing complex datasets generated during cell analysis.

2. By Technique

Flow Cytometry: A widely used technique for analyzing the physical and chemical characteristics of cells. It is instrumental in diagnosing blood cancers and assessing immune system health.

Microscopy: This traditional method provides detailed images of cells, helping researchers observe cellular structures and interactions.

High-Content Screening (HCS): An automated technique that combines cell analysis with image analysis, allowing for high-throughput screening of biological samples.

Polymerase Chain Reaction (PCR): PCR is used for amplifying DNA sequences, making it a key tool in genetic analysis and disease diagnosis.

3. By Application

Cancer Research: Cell analysis is extensively used in oncology for studying cancer cell biology, understanding tumor microenvironments, and developing new therapies.

Drug Discovery and Development: In drug research, cell analysis is crucial for evaluating the effects of potential drugs on cellular functions and viability.

Immunology: Cell analysis helps in studying immune cell functions, enabling the development of vaccines and treatments for autoimmune diseases.

Stem Cell Research: Researchers use cell analysis to characterize stem cells, study their differentiation processes, and explore their therapeutic potential.

4. By End User

Pharmaceutical and Biotechnology Companies: These companies rely on cell analysis for drug development, testing, and quality control.

Research Institutes: Academic and government research institutions utilize cell analysis for fundamental and applied research.

Hospitals and Clinical Laboratories: These settings use cell analysis for diagnostic purposes and monitoring disease progression.

Emerging Trends in the Cell Analysis Market

1. Growing Adoption of Single-Cell Analysis

Single-cell analysis is an emerging trend that provides insights into individual cellular behaviors and heterogeneity. It is gaining traction in oncology, immunology, and neurology research, where understanding individual cell responses can lead to more effective treatments.

2. Integration of Artificial Intelligence (AI) and Machine Learning

The integration of AI and machine learning in cell analysis is enhancing data interpretation. These technologies can quickly analyze large datasets, identify patterns, and predict outcomes, making the research process faster and more accurate.

3. Expansion of 3D Cell Culture Techniques

3D cell cultures offer a more realistic model of cellular environments compared to traditional 2D cultures. This technique is increasingly used in drug testing and cancer research, providing better insights into cellular behaviors in a three-dimensional context.

4. Rising Focus on Point-of-Care (POC) Diagnostics

The demand for rapid and accurate point-of-care diagnostics is growing, especially for detecting infectious diseases. POC devices utilizing cell analysis technologies are being developed to provide quick results in clinical settings, improving patient care and treatment outcomes.

Challenges in the Cell Analysis Market

1. High Costs of Instruments and Reagents

The high costs associated with advanced instruments and consumables can be a barrier for small and medium-sized research facilities. The expense of maintaining and upgrading equipment also adds to the financial burden.

2. Complexity of Data Analysis

Cell analysis generates vast amounts of data, making analysis complex and time-consuming. Interpreting this data accurately requires specialized software and expertise, posing challenges for researchers.

3. Regulatory Hurdles

Strict regulatory requirements for clinical trials and diagnostics can slow down the adoption of new cell analysis techniques. Companies must navigate complex regulatory pathways to bring their products to market.

Future Opportunities in the Cell Analysis Market

1. Expansion in Emerging Markets

Emerging economies in Asia-Pacific and Latin America present significant growth opportunities due to increasing investments in healthcare infrastructure and research activities.

2. Development of Advanced Imaging Techniques

Innovations in imaging techniques, such as super-resolution microscopy and live-cell imaging, are expected to open new avenues for research, providing deeper insights into cellular mechanisms.

3. Personalized Cancer Therapies

With the rise of personalized medicine, cell analysis is playing a critical role in developing individualized cancer treatments. Companies focusing on this niche are likely to see substantial growth in the coming years.

FAQs

1. What are the main techniques used in cell analysis? The primary techniques include flow cytometry, microscopy, high-content screening, and PCR, each offering unique advantages for specific applications.

2. How is cell analysis used in cancer research? In cancer research, cell analysis helps in understanding tumor cell behavior, identifying biomarkers, and developing targeted therapies.

3. What challenges does the cell analysis market face? The main challenges include high costs of instruments, complexity in data analysis, and stringent regulatory requirements.

4. What role does AI play in cell analysis? AI enhances data analysis by identifying patterns, predicting outcomes, and accelerating the research process, improving the accuracy and efficiency of cell analysis.

5. Which regions are expected to see the most growth in this market? The Asia-Pacific region is expected to witness significant growth due to increasing investments in healthcare infrastructure and rising demand for advanced diagnostic technologies.

Customize This Report As Per Your Requirement @ https://intentmarketresearch.com/ask-for-customization/cell-analysis-market-3147.html

About Us:

Intent Market Research (IMR) is designed to offer unique market insights, with a core focus on sustainable and inclusive growth of our clients. We offer comprehensive market research reports and consulting services to help our clients to take data-driven business decisions.

Our market intelligence reports offer fact-based and relevant insights across a range of industries including chemicals & materials, healthcare, food & beverage, automotive & transportation, energy & power, packaging, industrial equipment, building & construction, aerospace & defense, semiconductor & electronics to name a few.

Our approach is deeply collaborative, working closely with clients to drive transformative change that benefits all stakeholders and has positive impacts. With a strong emphasis on innovation, we’re here to help businesses grow, build sustainable advantages, and bring remarkable changes.

1846 E Innovation Park DR Site

100 ORO Valley AZ 85755

Email: [email protected]

Phone: +1 463-583-2713

#Cell Analysis Market

0 notes

jayanthitbrc · 3 days ago

Text

External Pacemakers Market Growth: Analysis of Demand, Innovation, and Future Prospects

The external pacemakers global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

External Pacemakers Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The external pacemakers market size has grown strongly in recent years. It will grow from $1.44 billion in 2023 to $1.52 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the shift towards less invasive surgical techniques, the demand for minimally invasive structural heart devices, ongoing training and education programs for healthcare professionals, rising healthcare expenditure, growing patient preference for non-surgical or minimally invasive treatment options.

The external pacemaker market size is expected to see strong growth in the next few years. It will grow to $1.90 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, timely regulatory approvals for new structural heart devices. Major trends in the forecast period include increasing adoption of transcatheter valve replacement, ongoing development of innovative devices with advanced materials, growing emphasis on personalized treatment approaches, increasing adoption of hybrid procedures, integration of remote monitoring and telehealth solutions.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/external-pacemakers-global-market-report

Scope Of External Pacemakers MarketThe Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

External Pacemakers Market Overview

Market Drivers -The growing incidence of cardiovascular diseases are expected to drive the growth of the external pacemaker market going forward. Cardiovascular disease (CVD) is a class of diseases involving the heart or blood vessels. There is a growing incidence of cardiovascular diseases due to several factors such as sedentary lifestyles, poor dietary habits high in processed foods and sugars, increasing rates of obesity, smoking, high blood pressure, and stress. The external pacemakers are used in cardiovascular diseases to regulate abnormal heart rhythms and improve cardiac function. For instance, in October 2022, according to the World Heart Federation, a Switzerland-based non-governmental organization, the projections indicate a rise in cardiovascular disease (CVD) deaths from 18.9 million in 2020 to surpass 22.2 million by 2030 and to escalate to 32.3 million by 2050. Therefore, the growing incidence of cardiovascular diseases is expected to propel the growth of the external pacemaker market.

Market Trends - Major companies operating in the external pacemaker market are developing innovative products, such as miniaturized pacemakers, to improve battery life and gain a competitive edge in the market. Miniaturized or leadless pacemakers are small electronic devices implanted in the heart to regulate its rhythm. For instance, in May 2023, Medtronic Plc, an Ireland-based medical device company, received Food and Drug Administration approval for Micra AV2 and Micra VR2, the next generation of its industry-leading miniaturized, leadless pacemakers. They provide up to 40% more battery life than previous models, with projected median battery life ranging from nearly 16 to 17 years. These devices feature advanced algorithms for automatic AV synchrony programming and higher tracking capability for active patients. Micra pacemakers minimize complications and improve the patient experience with their small size and lack of leads or surgical pockets.

The external pacemakers market covered in this report is segmented –

1) By Product: Single Chamber, Dual Chamber 2) By Application: Bradycardia, Acute Myocardial Infarction 3) By End-user: Hospitals, Ambulatory Surgical Centers, Other End-Users

Get an inside scoop of the external pacemakers market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15807&type=smp

Regional Insights - North America was the largest region in the external peacemakers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the external pacemakers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Key Companies - Major companies operating in the external pacemakers market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Fluke Corporation, W. L. Gore & Associates Inc., Lepu Medical Technology Co.Ltd., Biotronik, LivaNova PLC, ZOLL Medical Corporation, CryoLife Inc., OSCOR Inc., Sorin Group, Netech Corporation, Cosmos Healthcare, FIAB SpA, Soma Tech Intl, JenaValve Technology Inc., Ancora Heart Inc., Shree Pacetronix Ltd., Osypka Medical Inc., Avery Biomedical Devices Inc., Galix Biomedical Instrumentation Inc, AtaCor Medical Inc., Cor Medical Centre, Navilyst Medical Inc.

Table of Contents 1. Executive Summary 2. External Pacemakers Market Report Structure 3. External Pacemakers Market Trends And Strategies 4. External Pacemakers Market – Macro Economic Scenario 5. External Pacemakers Market Size And Growth ….. 27. External Pacemakers Market Competitor Landscape And Company Profiles28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: [email protected]

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

0 notes

healthcarefuture · 4 days ago

Text

Innovations Transforming the Prenatal Diagnostics Market Landscape

Prenatal Diagnostics refers to a range of medical tests and procedures conducted during pregnancy to assess the health of the fetus. The primary goal is to detect any genetic abnormalities, chromosomal disorders, or other potential health issues early on, enabling parents and healthcare providers to make informed decisions about care. These diagnostics are essential for ensuring the well-being of both the mother and the baby, offering insights into conditions like Down syndrome, cystic fibrosis, neural tube defects, and other congenital anomalies.

The Prenatal Diagnostics Market Size was projected to reach 16.02 billion USD in 2022, according to MRFR analysis. By 2032, the prenatal diagnostics market is projected to have grown from 16.79 billion USD in 2023 to 25.7 billion USD. Over the course of the forecast period (2024–2032), the prenatal diagnostics market is anticipated to develop at a CAGR of approximately 4.84%.

Prenatal diagnostics can be broadly classified into screening tests and diagnostic tests. Screening tests, such as blood tests and ultrasounds, are non-invasive and provide an assessment of the risk of certain conditions. In contrast, diagnostic tests like amniocentesis and chorionic villus sampling (CVS) are more invasive but provide definitive information about genetic abnormalities.

Size and Share of the Prenatal Diagnostics Market

The Prenatal Diagnostics market has experienced significant growth over the past decade and is projected to continue expanding. As of recent reports, the global market size was estimated at over USD 5 billion in 2023, with an anticipated compound annual growth rate (CAGR) of approximately 10% from 2024 to 2030. The increasing demand for non-invasive prenatal testing (NIPT), advancements in genetic screening technologies, and rising awareness about prenatal health are major factors driving this growth.

North America holds the largest market share due to advanced healthcare infrastructure, high adoption rates of prenatal testing, and robust healthcare policies. Europe follows closely, with increasing government support for early genetic testing and a growing aging maternal population. The Asia-Pacific region is expected to witness the fastest growth due to rising healthcare investments, improving diagnostic capabilities, and an increasing number of pregnancies in countries like India and China.

Prenatal Diagnostics Analysis

The Prenatal Diagnostics market analysis reveals a dynamic landscape characterized by rapid technological advancements, increasing consumer awareness, and a focus on non-invasive testing methods. Non-invasive prenatal testing (NIPT) has emerged as a game-changer, offering a safer, more accessible option for detecting chromosomal abnormalities. The test analyzes cell-free fetal DNA circulating in the maternal blood to identify potential genetic conditions, making it less risky than invasive methods like amniocentesis.

Technological innovations, such as the development of next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques, have enhanced the accuracy and efficiency of prenatal tests. The integration of artificial intelligence (AI) and machine learning in data analysis is further improving the reliability of diagnostic results, reducing false positives, and enabling personalized risk assessments.

Furthermore, regulatory approvals and increasing investment in research and development (R&D) are driving market growth. Companies are investing in developing cost-effective, efficient, and less invasive diagnostic solutions, catering to the rising demand from expecting parents.

Prenatal Diagnostics Trends

Several key trends are shaping the Prenatal Diagnostics market:

Rising Demand for Non-Invasive Testing: With the increasing awareness of the risks associated with invasive procedures, there is a growing preference for non-invasive prenatal testing (NIPT), which poses no risk to the fetus and offers early detection of chromosomal abnormalities.

Technological Advancements: The adoption of advanced genetic sequencing technologies, including next-generation sequencing (NGS) and microarray analysis, is enhancing the accuracy and scope of prenatal diagnostics. These technologies allow for more detailed genetic profiling, improving diagnostic outcomes.

Increased Awareness and Early Detection: Public health initiatives and educational campaigns are raising awareness about the importance of prenatal care, leading to higher adoption rates of prenatal diagnostic tests. Early detection enables timely interventions, improving maternal and fetal outcomes.

Integration of AI and Machine Learning: The application of AI in prenatal diagnostics is streamlining the interpretation of complex genetic data, reducing human error, and enabling more precise risk stratification. AI algorithms are improving diagnostic accuracy, particularly in complex cases with ambiguous results.

Expansion in Emerging Markets: The growing healthcare infrastructure in emerging markets, coupled with rising disposable income and increased awareness about prenatal care, is driving the adoption of prenatal diagnostic tests in these regions.

Reasons to Buy Prenatal Diagnostics Market Reports

Comprehensive Market Insights: Obtain a detailed analysis of the Prenatal Diagnostics market, including size, share, growth potential, and competitive landscape, to make informed business decisions.

Up-to-Date Market Trends: Stay updated on the latest technological advancements, emerging trends, and regulatory developments shaping the prenatal diagnostics industry.

Strategic Planning: Gain insights into key growth drivers, challenges, and opportunities in the market to develop effective business strategies and investment plans.

Competitive Analysis: Understand the competitive landscape, including key players, their market strategies, and innovations, to identify potential partnerships or areas for investment.

Market Forecast and Predictions: Access accurate market forecasts to anticipate future developments and adjust business strategies accordingly.

Recent Developments in Prenatal Diagnostics

Advancement in NIPT Technology: Companies have been developing advanced NIPT solutions that offer higher sensitivity and specificity, reducing the need for follow-up invasive testing.

Regulatory Approvals: Recent approvals by regulatory bodies like the FDA have expanded the use of certain prenatal tests, making them more widely available and reliable for detecting a broader range of genetic disorders.

AI Integration: The integration of AI in prenatal diagnostics is enhancing data analysis capabilities, providing more accurate and timely results to healthcare providers and patients.

Expansion into Emerging Markets: Major players are increasingly investing in emerging markets to tap into the growing demand for prenatal diagnostics, driven by rising healthcare awareness and improved medical infrastructure.

Collaborations and Partnerships: Key industry players are forming strategic collaborations with biotech companies and research institutions to advance prenatal diagnostic technologies and expand their product offerings.

The Prenatal Diagnostics market is poised for substantial growth as innovations continue to enhance the accuracy, accessibility, and safety of prenatal testing, ultimately improving maternal and fetal health outcomes.

rElated reports:

Dental Contouring Market

Dermatology Drug Market

Facial Implant Market

Feeding Tube Market

Healthcare Informatics Market

Top of Form

Bottom of Form

0 notes

marketingreportz · 10 days ago

Text

DNA Diagnostics Market - Forecast(2024 - 2030)

Advancement in product design and technology has encouraged doctors and researchers to shift their focus from traditional diagnostic methods to novel technologies. Adoption of personalized medicines approach would positively influence the DNA diagnostics market in the near future. The optimization of sequencing technology can increase the market for DNA diagnostics.

Sample Request :

For a blog focused on DNA diagnostics, it’s essential to provide readers with valuable insights into genetic testing, its applications, ethical considerations, and the latest advancements in the field. Here’s a suggested structure for a blog post:

Title: Unraveling the Double Helix: A Guide to DNA Diagnostics

Briefly introduce DNA diagnostics and its significance in modern healthcare.

Mention how DNA testing has evolved from paternity tests to sophisticated diagnostics for personalized medicine.

What is DNA Diagnostics?

Explain what DNA diagnostics entails and how it works on a basic level.

Describe the types of tests available (e.g., genetic screening, ancestry, disease predisposition, pharmacogenomics).

Inquiry before buying :

Applications of DNA Diagnostics

Detail the primary areas where DNA diagnostics is applied:

Medical Diagnosis: Identifying genetic disorders or predispositions to conditions like cancer, cardiovascular diseases, etc.

Ancestry and Genealogy: How people are using DNA to learn about their roots.

Pharmacogenomics: Matching medications to individuals based on genetic profiles.

Prenatal Screening: Screening for genetic disorders in unborn babies.

How DNA Diagnostics Works

Break down the DNA diagnostic process:

Sample collection (saliva, blood).

Laboratory analysis.

Interpretation of results by experts.

The Pros and Cons of DNA Diagnostics

Pros: Early disease detection, personalized treatment, better understanding of one’s health.

Cons: Ethical concerns, privacy risks, potential for misuse of genetic data.

Schedule a call :

Future Trends in DNA Diagnostics

Discuss innovations such as CRISPR and other gene-editing technologies, advancements in predictive diagnostics, and potential future applications.

Buy Now :

Conclusion

Summarize the potential benefits of DNA diagnostics while urging readers to consider ethical implications.

Encourage readers to consult healthcare professionals before using DNA diagnostics services.

Geographic regions analyzed for DNA diagnostics market is divided into four sections i.e. North America, Europe, Asia Pacific and Rest of the World. An increased adoption of the DNA diagnostics technology, availability of infrastructure, growing awareness on timely diagnosis and possibility for more precise results are the driving factors for the market in North America and Europe. Asia Pacific is expected to show fastest growth in the future due to high funding by government in healthcare facilities that enable advancement in R&D and introduction of new technology.

This report identifies global DNA diagnostics market on the basis of technology, application and regional market as follows:

DNA diagnostics market is segmented based on technology include polymerase chain reaction (PCR), microarrays, lab-on-chip or biochips and in situ hybridization technologies are some of the major DNA diagnostics techniques available

Based on applications of DNA diagnostics — detection of mutations, disease causing genes, diagnosing monogenic disorders, etc.

This report is further segmented based on potential markets for DNA diagnostics. A detailed analysis by region — United States, Europe, Asia-Pacific (APAC) and Rest of the World (RoW), has been provided in this report.

For more information of DNA Diagnostics Market click here

#DNADiagnostics #GeneticTesting #PersonalizedMedicine #Biotech #Genomics

0 notes

businessmarketreports · 11 days ago

Text

An Overview of Next Generation Sequencers Market: Trends and Insights

The Next-Generation Sequencers (NGS) market is witnessing rapid growth, driven by advancements in sequencing technology, declining costs, and increasing applications across healthcare, research, and agriculture. NGS enables high-throughput DNA sequencing, allowing for a more comprehensive analysis of genomes, transcriptomes, and epigenomes.

Buy Full Report for More Insights on the Next Generation Sequencers Market Forecast Download a Free Sample Report

This market encompasses various components, including instruments, software, and reagents, catering to a wide array of end-users, such as hospitals, research institutes, and biotechnology firms.

1. Market Overview

Market Size and Growth: The NGS market has shown robust growth due to rising demand for genomic analysis in personalized medicine, cancer research, and genetic diagnostics. Increasing adoption in clinical settings, along with advancements in technology, has driven accessibility and expanded market reach.

Regional Trends: North America and Europe currently dominate the market due to high healthcare expenditures, advanced infrastructure, and a significant focus on research and development. Meanwhile, Asia-Pacific is emerging as a promising market due to rising healthcare investments and increasing adoption of genomic medicine.

Key Applications: The major applications for NGS include oncology, infectious disease diagnostics, reproductive health, and hereditary disease screening, along with applications in agriculture and environmental studies.

2. Key Trends in the NGS Market

Declining Sequencing Costs: The costs of sequencing have significantly dropped since the advent of NGS technologies. The "thousand-dollar genome" has become a reality, making genetic testing more affordable and accessible, particularly in research and clinical diagnostics.

Shift Towards Clinical Applications: There is a growing demand for NGS in clinical settings, particularly in oncology for tumor profiling, hereditary disease detection, and pharmacogenomics. Clinical applications are gaining traction due to their potential for precision medicine, helping tailor treatments to individual genetic profiles.

Focus on Cancer Research: Oncology remains a major application area for NGS, as it enables detailed cancer genome analysis, leading to better understanding of mutations and tumor behavior. This technology supports both research and diagnostic applications, fueling demand among pharmaceutical companies and research institutes focused on oncology.

Rise of Liquid Biopsies: NGS is widely used in liquid biopsies, which offer a non-invasive method for cancer detection and monitoring by analyzing cell-free DNA (cfDNA) from blood samples. Liquid biopsies are gaining popularity as they allow real-time monitoring of tumor progression and treatment efficacy, reducing the need for invasive procedures.

Emergence of Long-Read Sequencing: Long-read sequencing technologies, such as those offered by Pacific Biosciences and Oxford Nanopore, are gaining traction due to their ability to provide more comprehensive genomic insights. These technologies are particularly valuable in detecting structural variants and resolving complex genomic regions.

Development of Companion Diagnostics: NGS-based companion diagnostics, used to determine the efficacy and safety of a specific drug for a targeted patient group, are expanding. These diagnostics guide treatment decisions in oncology, particularly for identifying biomarkers associated with certain therapies.

3. Market Segmentation

By Product: The NGS market includes sequencers, software, consumables, and services. Consumables, including reagents and kits, constitute the largest segment due to repeated purchases. However, software solutions are gaining traction as data analysis and interpretation become more complex.

By Technology:

Whole Genome Sequencing (WGS): WGS provides a comprehensive view of the entire genome, making it suitable for research and complex disease studies.

Targeted Sequencing: Targeted sequencing is cost-effective and focuses on specific regions of interest, widely used in oncology and clinical diagnostics.

RNA Sequencing: RNA sequencing enables transcriptome analysis and is valuable in cancer research, gene expression studies, and drug discovery.

Exome Sequencing: Exome sequencing, which targets protein-coding regions, is a more affordable alternative to WGS and is commonly used for diagnosing genetic disorders.

By Application: The NGS market serves several applications, including oncology, infectious disease diagnosis, reproductive health, genetic screening, and forensic analysis. Oncology holds the largest share, while infectious disease applications, particularly in tracking pathogens and outbreaks, are rapidly growing.

By End User: The primary end-users include academic and research institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and government agencies. Hospitals and clinics are showing increasing demand as NGS technology moves from research into clinical diagnostics.

4. Key Drivers and Challenges

Drivers:

Increased Demand for Precision Medicine: The trend toward personalized medicine is a major driver, as NGS allows for tailored treatments based on genetic profiles, improving treatment outcomes.

Growing Investment in Genomic Research: Governments, healthcare institutions, and private companies are heavily investing in genomic research and infrastructure to support NGS applications across various fields.

Expansion of Genetic Screening Programs: Many countries are implementing large-scale genetic screening programs for early detection of genetic disorders and hereditary cancers, boosting demand for NGS.

Challenges:

Data Management and Analysis Complexity: The high volume of data generated by NGS requires advanced bioinformatics solutions for analysis, interpretation, and storage. This creates a need for skilled personnel and sophisticated software.

Regulatory and Ethical Concerns: The regulatory landscape for NGS is evolving, and concerns regarding data privacy and ethical issues are prevalent. Obtaining regulatory approval for clinical NGS applications can be time-consuming.

High Initial Investment: Although sequencing costs have decreased, the initial investment required for NGS platforms and bioinformatics infrastructure remains high, limiting adoption in resource-constrained regions.

5. Competitive Landscape

The NGS market is highly competitive, with established players as well as new entrants focusing on niche applications. Key players are investing in research and development, collaborations, and acquisitions to strengthen their market positions and expand product portfolios.

Illumina, Inc.: Illumina is the market leader, with a dominant position in sequencing instruments and consumables. Its sequencers, including the NovaSeq and NextSeq series, are widely used in research and clinical settings.

Thermo Fisher Scientific, Inc.: Known for its Ion Torrent platform, Thermo Fisher focuses on providing affordable, high-throughput sequencing solutions, with applications ranging from cancer research to infectious disease diagnostics.

Pacific Biosciences: PacBio specializes in long-read sequencing technology, particularly valuable for applications that require high accuracy in structural variant detection. Its Sequel system is popular among researchers in complex genomics.

Oxford Nanopore Technologies: Oxford Nanopore offers portable, real-time sequencing devices like the MinION and PromethION, which are particularly useful for field-based applications and rapid sequencing needs.

BGI Group: Based in China, BGI is a major player in genome sequencing services and provides a range of sequencers tailored for research and clinical applications. Its focus on affordability has helped it gain traction in emerging markets.

Qiagen N.V.: Qiagen provides NGS sample preparation and bioinformatics solutions, with a particular emphasis on clinical diagnostics. Its GeneReader NGS System is aimed at making NGS more accessible in clinical labs.

Agilent Technologies: Agilent offers NGS target enrichment and analysis solutions, focusing on workflows for oncology and hereditary disease testing.

6. Future Outlook

Advancements in Data Analysis Tools: Continued improvements in bioinformatics and artificial intelligence are expected to streamline data interpretation, making NGS more accessible to clinical users and reducing the time required for analysis.

Rise of Multi-Omics Approaches: Multi-omics, which combines genomics with proteomics, transcriptomics, and metabolomics, is expected to enhance the understanding of complex diseases. NGS will play a key role in integrating genomic data with other molecular insights.

Increased Focus on Rare Disease Research: NGS enables the identification of mutations associated with rare genetic disorders, facilitating research and development of targeted therapies. This area is likely to see continued growth, especially as pharmaceutical companies invest in precision medicine.

Expansion of Direct-to-Consumer (DTC) Testing: DTC genetic testing is gaining popularity, and as NGS becomes more affordable, companies may offer more comprehensive and affordable sequencing-based consumer tests.

Development of Point-of-Care Sequencing: Point-of-care NGS devices, offering rapid and portable sequencing capabilities, could find applications in emergency rooms and remote locations, particularly for infectious disease diagnosis.

Conclusion

The NGS market is positioned for substantial growth, driven by its expanding role in clinical diagnostics, advancements in sequencing technology, and increasing affordability. Applications in cancer research, infectious disease detection, and reproductive health are set to grow as the technology becomes more integrated into healthcare systems worldwide. However, challenges such as data complexity and regulatory hurdles will require ongoing innovation in bioinformatics and clear guidelines for clinical use. As technology advances, NGS has the potential to become a routine tool in personalized medicine, facilitating earlier diagnosis, better treatments, and improved patient outcomes across a range of medical fields.

#Next-Generation Sequencers (NGS) market

0 notes